Blood Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Antisense Technology
Promoter hypomethylation marks the progression of chronic myeloid leukemia
December 29th, 2005
A study from Spain has reported that promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia (CML). J. Roman-Gomez and colleagues, Reina Sofia Hospital, wrote, "Aberrant genome-wide hypomethylation is thought to be related to tumorigenesis by promoting genomic instability. Since DNA methylation is considered an important mechanism for the silencing of retroelements, hypomethylation in human tumors may lead to their reactivation." "However, the role of DNA hypomethylation in CML remains to be elucidated. In this study, the methylation status of the...
Source: Blood Weekly (2005-12-29)
|
